These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 25047176)
1. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382 [TBL] [Abstract][Full Text] [Related]
4. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233 [TBL] [Abstract][Full Text] [Related]
5. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999 [TBL] [Abstract][Full Text] [Related]
6. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441 [TBL] [Abstract][Full Text] [Related]
7. A four-gene signature predicts survival in clear-cell renal-cell carcinoma. Dai J; Lu Y; Wang J; Yang L; Han Y; Wang Y; Yan D; Ruan Q; Wang S Oncotarget; 2016 Dec; 7(50):82712-82726. PubMed ID: 27779101 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070 [TBL] [Abstract][Full Text] [Related]
9. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152 [TBL] [Abstract][Full Text] [Related]
11. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? Soultati A; Stares M; Swanton C; Larkin J; Turajlic S Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509 [TBL] [Abstract][Full Text] [Related]
12. Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. Sanjmyatav J; Matthes S; Muehr M; Sava D; Sternal M; Wunderlich H; Gajda M; Grimm MO; Junker K Br J Cancer; 2014 May; 110(10):2537-43. PubMed ID: 24667645 [TBL] [Abstract][Full Text] [Related]
13. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079 [TBL] [Abstract][Full Text] [Related]
15. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma. Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688 [TBL] [Abstract][Full Text] [Related]
16. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. Büttner F; Winter S; Rausch S; Reustle A; Kruck S; Junker K; Stenzl A; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E Eur Urol; 2015 Dec; 68(6):1016-20. PubMed ID: 26072688 [TBL] [Abstract][Full Text] [Related]
17. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077 [TBL] [Abstract][Full Text] [Related]
18. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma. Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605 [TBL] [Abstract][Full Text] [Related]
19. Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. Saout JR; Lecuyer G; Léonard S; Evrard B; Kammerer-Jacquet SF; Noël L; Khene ZE; Mathieu R; Brunot A; Rolland AD; Bensalah K; Rioux-Leclercq N; Lardenois A; Chalmel F Eur Urol; 2023 May; 83(5):441-451. PubMed ID: 36801089 [TBL] [Abstract][Full Text] [Related]
20. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics. Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]